Lipella Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Lipella Pharmaceuticals Inc. (LIPO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.00 per share for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-11-14
- Lipella Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Lipella Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $4.40, a 54.93% increase year-over-year.
- Lipella Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-06-30 was $2.19.
- Lipella Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $2.84, a 0.00% change year-over-year.
- Lipella Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $4.40, a 74.89% decline from fiscal 2023.
- Lipella Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $17.52, a 516.90% increase from fiscal 2022.
- Lipella Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.84, a 1.07% increase from fiscal 2021.
- Lipella Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $2.81.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | |||||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | |||||||
| 2024-12-31 | $4.40 10-K · filed 2025-03-28 | |||||||
| 2024-09-30 | $4.40 10-Q · filed 2025-11-14 | |||||||
| 2024-06-30 | $4.40 10-Q · filed 2025-08-14 | $0.55 10-Q · filed 2024-08-13 | ||||||
| 2024-03-31 | $4.40 10-Q · filed 2025-05-14 | $0.55 10-Q · filed 2024-05-09 | ||||||
| 2023-12-31 | $17.52 10-K · filed 2025-03-28 | $2.19 10-K · filed 2024-02-27 | ||||||
| 2023-09-30 | $17.52 10-Q · filed 2024-11-14 | $2.19 10-Q · filed 2023-11-14 | ||||||
| 2023-06-30 | $2.19 10-Q · filed 2023-11-14 | $2.84 10-Q · filed 2024-08-13 | $2.19 10-Q · filed 2023-08-14 | |||||
| 2023-03-31 | $2.84 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | $2.84 10-K · filed 2024-02-27 | |||||||
| 2022-09-30 | $2.84 10-Q · filed 2023-11-14 | |||||||
| 2022-06-30 | $2.84 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | $2.84 10-Q · filed 2023-05-12 | |||||||
| 2021-12-31 | $2.81 10-K · filed 2023-03-31 |